Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Book

Alogliptin

Jamie M. Terrell  1 , Preeti Patel, Tibb F. Jacobs  2
In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
.
Affiliations
Free Books & Documents
Book

Alogliptin

Jamie M. Terrell et al.
Free Books & Documents

Excerpt

Alogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, was approved by the US Food and Drug Administration (FDA) to help improve glycemic control in adults with type 2 diabetes (T2D) when used alongside diet and exercise. Alogliptin enhances insulin secretion and reduces glucagon levels by prolonging incretin hormone activity. This drug selectively inhibits DPP-4 without affecting DPP-8 or DPP-9, thereby minimizing off-target toxicity. Alogliptin is available as an oral tablet and is administered once daily. Contraindications include hypersensitivity reactions such as anaphylaxis and angioedema.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Jamie Terrell declares no relevant financial relationships with ineligible companies.

Disclosure: Preeti Patel declares no relevant financial relationships with ineligible companies.

Disclosure: Tibb Jacobs declares no relevant financial relationships with ineligible companies.

References

    1. Smyth B, Perkovic V. New hypoglycemic agents and the kidney: what do the major trials tell us? F1000Res. 2018;7 - PMC - PubMed
    1. Cheng JWM, Colucci VJ, Kalus JS, Spinler SA. Managing Diabetes and Preventing Heart Disease: Have We Found a Safe and Effective Agent? Ann Pharmacother. 2019 May;53(5):510-522. - PubMed
    1. Zhu B, Li Y, Mei W, He M, Ding Y, Meng B, Zhao H, Xiang G. Alogliptin improves endothelial function by promoting autophagy in perivascular adipose tissue of obese mice through a GLP-1-dependent mechanism. Vascul Pharmacol. 2019 Apr;115:55-63. - PubMed
    1. Park JY, Lee J, Choi YH, Min KW, Han KA, Ahn KJ, Lim S, Kim YH, Ahn CW, Choi KM, Yoon KH. Efficacy and Safety of Alogliptin-Pioglitazone Combination for Type 2 Diabetes Mellitus Poorly Controlled with Metformin: A Multicenter, Double-Blind Randomized Trial. Diabetes Metab J. 2024 Sep;48(5):915-928. - PMC - PubMed
    1. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022 May 03;79(17):e263-e421. - PubMed

Publication types

LinkOut - more resources